Suzhou Unigreen Electronic Technology Co., Ltd.

Established in 2015, our factory is a pioneering company specializing in clinical medicine-oriented recombinant collagen. We operate a comprehensive industry chain platform, integrating biosynthesis and medical device transformation capabilities. Boasting five authorized patents for our recombinant collagen core sequences, Trautec is steadfastly dedicated to research and development, manufacturing, and the distribution of innovative biomaterials, novel proteins, nucleic acid drugs, and dietary products.

Our corporate headquarters, strategically located in Jiangsu, China, spans a sprawling 100, 000 square feet facility. We have invested over $17 million solely in advancing the production of recombinant human collagen (ReCol 3®) and (ReCol 17®).

We are resolute in our mission to make ReCol 3® and ReCol 17® universally accessible and applicable, particularly within the personal care industry, with a primary focus on cosmetics and medical regeneration sectors. As ReCol3® continues to evolve, Trautec's dedication to upholding the same core principles remains steadfast: to lead the forefront of SRHC while delivering a sustainable, collagen-based biomaterial that is both effective and safe.

At present, our factory proudly holds five patents related to recombinant collagen core sequences within the realm of recombinant collagen, Our commitment to innovation in synthetic biology serves as the cornerstone for the exploration of novel biological materials catering to repair, regeneration, anti-aging, and disease treatment.

Our state-of-the-art R&D platform features autonomous molecular biology laboratories, facilities for protein and nucleic acid purification, a dedicated cell culture suite, high-performance liquid chromatography analysis laboratories, and cutting-edge high-throughput screening technologies. Our global sales volume for recombinant collagen XVII raw materail :20 tons ranked Top 1 approved by Frost & Sullivan in 2023